Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

Gram Positive Bacterial Infection Clinical Trial

Official title: An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics

Status Completed

Clinical Trial Summary

This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected infections that are caused by a specific group of bacteria (called Gram-positive bacteria)or perioperative subjects that are receiving prophylactic antibiotics .

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Bacterial Infections
• Communicable Diseases
• Gram Positive Bacterial Infection
• Gram-Positive Bacterial Infections
• Infection

• NCT number: NCT01019395
• Study type: Interventional
• Source: Cubist Pharmaceuticals LLC
• Status: Completed
• Phase: Phase 1
• Start date: January 5, 2010
• Completion date: March 20, 2012